SDS-PAGE gel of Biotinylated Human PADI4 Protein (Primary Amine Labelin 3086

Biotinylated Human PADI4 Protein (Primary Amine Labeling) 3086

$675.00 – $2,250.00

Summary

Expression: E.coli
Pure: Yes (SDS-PAGE)
Amino Acid Range: Met1-Pro663

SKU: 3086parent Categories: proteins, Recombinant proteins Tag: active proteins

Weight	1 lbs
Dimensions	9 × 5 × 2 in
express system	E.coli
product tag	N-His
purity	> 95% as determined by Tris-Bis PAGE
background	Peptidylarginine deiminase type4 (PADI4) was firstly identified as a non-MHC RA genetic risk factor. Furthermore, PADI4 risk allele possessed the association with bone damage regardless of anti citrullinated peptide antibody (ACPA) positivity in Asian RA patients. PADI4 gene codes PAD4 protein which has post-translational modification activity (citrullination). Padi4 is mainly expressed in myeloid cells and granulocytes.
molecular weight	The protein has a predicted MW of 76.6 kDa same as Tris-Bis PAGE result.
available size	100 µg, 500 µg
endotoxin	Less than 1EU per μg by the LAL method.

Biotinylated Human PADI4 Protein (Primary Amine Labeling) 3086

protein

Size and concentration 100, 500µg and liquid
Form Liquid
Storage Instructions Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Storage buffer Shipped with dry ice.
Purity > 95% as determined by Tris-Bis PAGE

target relevance
Peptidylarginine deiminase type4 (PADI4) was firstly identified as a non-MHC RA genetic risk factor. Furthermore, PADI4 risk allele possessed the association with bone damage regardless of anti citrullinated peptide antibody (ACPA) positivity in Asian RA patients. PADI4 gene codes PAD4 protein which has post-translational modification activity (citrullination). Padi4 is mainly expressed in myeloid cells and granulocytes.
Protein names Protein-arginine deiminase type-4 (EC 3.5.3.15) (HL-60 PAD) (Peptidylarginine deiminase IV) (Protein-arginine deiminase type IV)
Gene names PADI4,PADI4 PAD4 PADI5 PDI5
Protein family Protein arginine deiminase family
Mass 9606Da
Function Catalyzes the citrullination/deimination of arginine residues of proteins such as histones, thereby playing a key role in histone code and regulation of stem cell maintenance (PubMed:15339660, PubMed:15345777, PubMed:16567635, PubMed:21245532). Citrullinates histone H1 at 'Arg-54' (to form H1R54ci), histone H3 at 'Arg-2', 'Arg-8', 'Arg-17' and/or 'Arg-26' (to form H3R2ci, H3R8ci, H3R17ci, H3R26ci, respectively) and histone H4 at 'Arg-3' (to form H4R3ci) (PubMed:15339660, PubMed:15345777, PubMed:16567635, PubMed:21245532). Acts as a key regulator of stem cell maintenance by mediating citrullination of histone H1: citrullination of 'Arg-54' of histone H1 (H1R54ci) results in H1 displacement from chromatin and global chromatin decondensation, thereby promoting pluripotency and stem cell maintenance (PubMed:15339660, PubMed:15345777, PubMed:16567635, PubMed:21245532). Promotes profound chromatin decondensation during the innate immune response to infection in neutrophils by mediating formation of H1R54ci (PubMed:18209087). Required for the formation of neutrophil extracellular traps (NETs); NETs are mainly composed of DNA fibers and are released by neutrophils to bind pathogens during inflammation (By similarity). Citrullination of histone H3 prevents their methylation by CARM1 and HRMT1L2/PRMT1 and represses transcription (PubMed:15345777). Citrullinates EP300/P300 at 'Arg-2142', which favors its interaction with NCOA2/GRIP1 (PubMed:15731352).
Catalytic activity BINDING 153; /ligand="Ca(2+)"; /ligand_id="ChEBI:CHEBI:29108"; /ligand_label="1"; /evidence="ECO:0000269\|PubMed:15247907, ECO:0000269\|PubMed:16567635, ECO:0000269\|PubMed:17002273"; BINDING 155; /ligand="Ca(2+)"; /ligand_id="ChEBI:CHEBI:29108"; /ligand_label="1"; /evidence="ECO:0000269\|PubMed:15247907, ECO:0000269\|PubMed:16567635, ECO:0000269\|PubMed:17002273"; BINDING 155; /ligand="Ca(2+)"; /ligand_id="ChEBI:CHEBI:29108"; /ligand_label="2"; /evidence="ECO:0000269\|PubMed:15247907, ECO:0000269\|PubMed:16567635, ECO:0000269\|PubMed:17002273"; BINDING 157; /ligand="Ca(2+)"; /ligand_id="ChEBI:CHEBI:29108"; /ligand_label="1"; /evidence="ECO:0000269\|PubMed:15247907, ECO:0000269\|PubMed:16567635, ECO:0000269\|PubMed:17002273"; BINDING 157; /ligand="Ca(2+)"; /ligand_id="ChEBI:CHEBI:29108"; /ligand_label="2"; /evidence="ECO:0000269\|PubMed:15247907, ECO:0000269\|PubMed:16567635, ECO:0000269\|PubMed:17002273"; BINDING 165; /ligand="Ca(2+)"; /ligand_id="ChEBI:CHEBI:29108"; /ligand_label="1"; /evidence="ECO:0000269\|PubMed:15247907, ECO:0000269\|PubMed:16567635, ECO:0000269\|PubMed:17002273"; BINDING 165; /ligand="Ca(2+)"; /ligand_id="ChEBI:CHEBI:29108"; /ligand_label="3"; /evidence="ECO:0000269\|PubMed:15247907, ECO:0000269\|PubMed:16567635, ECO:0000269\|PubMed:17002273"; BINDING 168; /ligand="Ca(2+)"; /ligand_id="ChEBI:CHEBI:29108"; /ligand_label="3"; /evidence="ECO:0000269\|PubMed:15247907, ECO:0000269\|PubMed:16567635, ECO:0000269\|PubMed:17002273"; BINDING 170; /ligand="Ca(2+)"; /ligand_id="ChEBI:CHEBI:29108"; /ligand_label="3"; /evidence="ECO:0000269\|PubMed:15247907, ECO:0000269\|PubMed:16567635, ECO:0000269\|PubMed:17002273"; BINDING 176; /ligand="Ca(2+)"; /ligand_id="ChEBI:CHEBI:29108"; /ligand_label="1"; /evidence="ECO:0000269\|PubMed:15247907, ECO:0000269\|PubMed:16567635, ECO:0000269\|PubMed:17002273"; BINDING 179; /ligand="Ca(2+)"; /ligand_id="ChEBI:CHEBI:29108"; /ligand_label="1"; /evidence="ECO:0000269\|PubMed:15247907, ECO:0000269\|PubMed:16567635, ECO:0000269\|PubMed:17002273"; BINDING 179; /ligand="Ca(2+)"; /ligand_id="ChEBI:CHEBI:29108"; /ligand_label="2"; /evidence="ECO:0000269\|PubMed:15247907, ECO:0000269\|PubMed:16567635, ECO:0000269\|PubMed:17002273"; BINDING 349; /ligand="Ca(2+)"; /ligand_id="ChEBI:CHEBI:29108"; /ligand_label="4"; /evidence="ECO:0000269\|PubMed:15247907, ECO:0000269\|PubMed:16567635, ECO:0000269\|PubMed:17002273"; BINDING 351; /ligand="Ca(2+)"; /ligand_id="ChEBI:CHEBI:29108"; /ligand_label="5"; /evidence="ECO:0000269\|PubMed:15247907, ECO:0000269\|PubMed:16567635, ECO:0000269\|PubMed:17002273"; BINDING 353; /ligand="Ca(2+)"; /ligand_id="ChEBI:CHEBI:29108"; /ligand_label="4"; /evidence="ECO:0000269\|PubMed:15247907, ECO:0000269\|PubMed:16567635, ECO:0000269\|PubMed:17002273"; BINDING 369; /ligand="Ca(2+)"; /ligand_id="ChEBI:CHEBI:29108"; /ligand_label="5"; /evidence="ECO:0000269\|PubMed:15247907, ECO:0000269\|PubMed:16567635, ECO:0000269\|PubMed:17002273"; BINDING 370; /ligand="Ca(2+)"; /ligand_id="ChEBI:CHEBI:29108"; /ligand_label="5"; /evidence="ECO:0000269\|PubMed:15247907, ECO:0000269\|PubMed:16567635, ECO:0000269\|PubMed:17002273"; BINDING 373; /ligand="Ca(2+)"; /ligand_id="ChEBI:CHEBI:29108"; /ligand_label="5"; /evidence="ECO:0000269\|PubMed:15247907, ECO:0000269\|PubMed:16567635, ECO:0000269\|PubMed:17002273"; BINDING 374; /ligand="substrate"; /evidence="ECO:0000269\|PubMed:21882827"; BINDING 388; /ligand="Ca(2+)"; /ligand_id="ChEBI:CHEBI:29108"; /ligand_label="2"; /evidence="ECO:0000269\|PubMed:15247907, ECO:0000269\|PubMed:16567635, ECO:0000269\|PubMed:17002273"; BINDING 407; /ligand="Ca(2+)"; /ligand_id="ChEBI:CHEBI:29108"; /ligand_label="4"; /evidence="ECO:0000269\|PubMed:15247907, ECO:0000269\|PubMed:16567635, ECO:0000269\|PubMed:17002273"; BINDING 410; /ligand="Ca(2+)"; /ligand_id="ChEBI:CHEBI:29108"; /ligand_label="4"; /evidence="ECO:0000269\|PubMed:15247907, ECO:0000269\|PubMed:16567635, ECO:0000269\|PubMed:17002273"; BINDING 411; /ligand="Ca(2+)"; /ligand_id="ChEBI:CHEBI:29108"; /ligand_label="4"; /evidence="ECO:0000269\|PubMed:15247907, ECO:0000269\|PubMed:16567635, ECO:0000269\|PubMed:17002273"; BINDING 639; /ligand="substrate"; /evidence="ECO:0000269\|PubMed:21882827"
Subellular location Cytoplasm. Nucleus. Cytoplasmic granule. Note=Cytoplasmic granules of eosinophils and neutrophils.
Tissues Expressed in eosinophils and neutrophils, not expressed in peripheral monocytes or lymphocytes.
Post-translational modification Autocitrullination at Arg-372 and Arg-374 inactivates the enzyme.
Target Relevance information above includes information from UniProt accession: Q9UM07
The UniProt Consortium

SDS-PAGE gel of Biotinylated Human PADI4 Protein (Primary Amine Labelin

Biotinylated Human PADI4 (Primary Amine Labeling) on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.